% | $
Quotes you view appear here for quick access.

Rockwell Medical, Inc. Message Board

  • a_rajalonghorn a_rajalonghorn Jun 1, 2013 2:34 PM Flag

    RMTI Bull Analysis (part 3)

    Here is an excerpt from the companies website:

    "SFP has been designed to effectively address the current challenges in anemia management by:

    - Maintaining hemoglobin (Hgb) levels within a safe range using moderate ESA doses
    - Improving response to ESA therapy, while avoiding excessively high doses and potential risks
    -Preventing iron from being stored in the liver thereby avoiding liver toxicity
    -Reducing current drug administration costs

    SFP is intended to deliver iron directly to the bloodstream in small, continuous doses three times per week and is designed to replace the 5-7 mg of iron that is lost during every dialysis treatment. This mode of delivery maintains patient Hgb within a target range resulting in moderate ESA dose and improved ESA response. With current IV iron therapy, iron levels are not always adequate when ESA’s are dosed and therefore greater ESA doses are needed; this is believed to contribute to Hgb variability and related adverse consequences.

    SFP’s unique properties enable it to avoid storage in the liver upon dosing. Avoiding iron storage in the liver eliminates liver toxicity associated with current IV iron delivery. It is believed that approximately 50 percent of the IV iron that is dosed to a patient never leaves the liver and over time may cause adverse consequences. (Source: Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. JASN. 2007;18:975-984.)
    In addition to the potential to provide significant patient benefit and improved patient outcome, SFP is expected to reduce related healthcare costs considerably. Because SFP is delivered via dialysate, required supplies such as needles and syringes needed for current IV therapy are avoided and nursing time to deliver and manage IV iron is no longer needed.


    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
16.65+0.14(+0.85%)Jul 7 4:00 PMEDT